| Upfront | ATAC, BIG | |
| Switch | ITA, IES, ARNO 95 | |
| Sequenz | ABCSG-8, | |
| erweiterte Adjuvanz | ABCSG-6a, MA 17, NSABP B33 | |
Consort
ECOG /SWOG
FIRST
ATLAS
EvAluate
PreFace
Long-Term Follow-Up of the Intergroup Exemestane Study.
J Clin Oncol 2017;35:2507-2514
| endokrine adjuvante Therapie des Mamma - Karzinoms | |||||||||||
| allgemeines | |||||||||||
| Aromatasehemmer |
| ||||||||||
Consort |
Tamoxifen versus Exemestan | ||||||||||
| Nach 2-3a Tamoxifen: Tamoxifen versus Exemestan (1) | |||||||||||
| Exemestan | |||||||||||
| LHRH-Analogon + Tamoxifen versus Anastrozol +- Biphosphonat | |||||||||||
ECOG /SWOG |
CAF +- Tamoxifen, LHRH-Analogon | ||||||||||
FIRST |
Anastrozol versus Fulvestrant | ||||||||||
ATLAS |
Adjuvant Tamoxifen - Long Against Shorter, 5a versus 10 Jahre, 7000 Patientinnen: 10a: weniger Rezidive (331 v. 397, p = 0,01) und geringere Gesamtmortalität (539 versus 722, p= 0,01. Endometriumkarzinom häufiger (1,6 v. 3,1%), Endometriumkarzinom - Mortalität höher (0,2% v. 0,4%) | ||||||||||
EvAluate |
Evaluation des Femara-Therapiemanagement | ||||||||||
PreFace |
Teil von EvAluate. Predictive Factors for the Effectivity of Aromatase Inhibitor Therapy | ||||||||||
| Letrezol kontinuierlich versus Letrezol intermittierend nach 5 Jahren endokriner adjuvanter Behandlung. | |||||||||||
| Quellen |
1.) Morden JP, et al.: Long-Term Follow-Up of the Intergroup Exemestane Study. J Clin Oncol 2017;35:2507-2514 | ||||||||||
| |||||||||||
Impressum Zuletzt geändert am 28.12.2014 9:46